GSE123475
Knockdown of GRHL2 affects active enhancers (H3K27ac sites) enriched for ER binding
Differential ChIP-Seq data monitoring changes in active enhancer marks (H3K27ac sites) after treatment with siGRHL2 in MCF7 and T47D breast cancer models. Comparing sites altered by treatment with siGRHL2 after 48hours revealed these sites to be enriched for Estrogen Receptor (ER) binding. Overall design: ChIP-seq data monitoring H3K27ac in MCF7 and T47D cells after treatment with siGRHL2 and siCTRL for 48 hours.